Prime Medicine, Inc. (PRME) stock
PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.84−0.35 (-8.35%)
Close on Nov 17, 2026Market cap $696.49MP/E –Yield –
Prime Medicine price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Prime Medicine's price to sales ratio was 138.2× on Apr 30, 2026, against 76.1× a year earlier.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 138.2× | +33.5 |
| 2025 | Dec 31, 2025 | 104.7× | −374.1 |
| 2024 | Dec 31, 2024 | 478.7× | – |
See a number that looks wrong?